| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8835488 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(8 years from now) | |
| US9309234 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(8 years from now) | |
| US11077098 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9642842 | TREVENA | Opioid receptor ligands and methods of using and making same |
Mar, 2032
(8 years from now) | |
Olinvyk is owned by Trevena.
Olinvyk contains Oliceridine.
Olinvyk has a total of 4 drug patents out of which 0 drug patents have expired.
Olinvyk was authorised for market use on 30 October, 2020.
Olinvyk is available in solution;intravenous dosage forms.
Olinvyk can be used as management of acute pain by intravenous injection.
Drug patent challenges can be filed against Olinvyk from 2024-10-30.
The generics of Olinvyk are possible to be released after 23 March, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 30, 2025 |
Drugs and Companies using OLICERIDINE ingredient
NCE-1 date: 2024-10-30
Market Authorisation Date: 30 October, 2020
Treatment: Management of acute pain by intravenous injection
Dosage: SOLUTION;INTRAVENOUS
OLINVYK family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic